Organigram Global (OGI) vs Spruce Biosciences (SPRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Organigram Global (OGI) has outperformed Spruce Biosciences (SPRB) over the past year, losing 51.0% versus a loss of 75.7%. Over five years, OGI leads with a -89.3% price change compared with -99.8% for SPRB. Organigram Global is the larger company by market cap ($138.4 million vs $127.6 million), about 1.1 times the size.
On valuation, Spruce Biosciences trades at a lower forward P/E (8.9x vs 40.0x for Organigram Global).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OGI | SPRB |
|---|---|---|
| Share price | $0.96 | $44.40 |
| Market cap | $138.39M | $127.61M |
| 1-day change | -1.04% | +3.77% |
| YTD return | -42.86% | -49.03% |
| 1-year return | -51.02% | -75.68% |
| 5-year return | -89.29% | -99.82% |
| P/E ratio (TTM) | 2.23 | — |
| Forward P/E | 40.00 | 8.92 |
| EPS (TTM) | $0.43 | $-40.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.24 | $199.20 |
| 52-week low | $0.853 | $40.33 |
| Distance from 52-week high | -57.14% | -77.71% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | — | +233.33% |
| Average volume | 891.72K | 77.72K |
| Shares outstanding | 144.15M | 2.87M |
| Employees | 1,139 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OGI has outperformed SPRB by 24.7 percentage points over the past year.
About Organigram Global
OGI stock →Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,139 employees
About Spruce Biosciences
SPRB stock →Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
OGI vs SPRB FAQ
Which is bigger, Organigram Global or Spruce Biosciences?
Organigram Global (OGI) is larger, with a market capitalization of $138.39M compared with $127.61M for Spruce Biosciences (SPRB).
Which stock has performed better over the past year, OGI or SPRB?
OGI returned -51.02% over the past 12 months, compared with -75.68% for SPRB (price return, excluding dividends). Past performance does not predict future results.
Are Organigram Global and Spruce Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.